Lagevrio

Adult Dosing .

Dosage forms:  CAP: 200 mg

Investigational New Drug (IND)

[FDA emergency use authorization (EUA)]

Info: for mild-moderate COVID-19 in pts at high risk for severe dz incl. hospitalization or death, if alternative agents not accessible or clinically appropriate; not FDA approved; avail. from Merck & Co, Inc. or authorized distributors as directed by US government; for clinical trial eligibility and enrollment info, check www.clinicaltrials.gov

[mandatory reporting]

Info: serious medication errors and adverse events must be reported to FDA MedWatch (www.fda.gov/medwatch/report.htm or 1-800-FDA-1088) and Merck & Co, Inc. (dpoc.usa@msd.com)

COVID-19, mild-moderate

[800 mg PO q12h x5 days]

Start: ASAP w/in 5 days of sx onset; Info: for pts at high risk for severe dz incl. hospitalization or death, if alternative agents not accessible or clinically appropriate

renal dosing

[no adjustment]

renal impairment: no adjustment

HD/PD: no adjustment; no supplement

hepatic dosing

[no adjustment]

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.